PRESS RELEASE published on 05/31/2024 at 15:51, 1 year 10 months ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance effective June 7th, 2024, impacting ADS holders trading price Biopharmaceutical Company Nasdaq Compliance DBV Technologies ADS Ratio Change Food Allergies Treatment
BRIEF published on 05/17/2024 at 22:35, 1 year 10 months ago DBV Technologies Announces ADS Ratio Change Nasdaq Compliance Biopharmaceuticals Stock Adjustment DBV Technologies ADS Ratio Change
PRESS RELEASE published on 05/17/2024 at 22:30, 1 year 10 months ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance. The ADS Ratio Change will be effective on June 3rd, 2024, impacting ADS trading price. No impact on underlying ordinary shares Ordinary Shares Nasdaq Compliance DBV Technologies ADS Ratio Change Trading Price
BRIEF published on 05/16/2024 at 22:35, 1 year 11 months ago DBV Technologies announces the results of the 2024 Combined General Meeting General Assembly 2024 DBV Technologies Resolutions Adopted Allergy Treatment Biopharmaceutical Sector
PRESS RELEASE published on 05/16/2024 at 22:30, 1 year 11 months ago DBV Technologies Announces Results of its 2024 Combined General Meeting DBV Technologies announces successful results of its 2024 Combined General Meeting where shareholders approved all proposed resolutions. The Company focuses on treatment options for food allergies Resolutions Combined General Meeting DBV Technologies Food Allergies Treatment Options
BRIEF published on 05/09/2024 at 22:35, 1 year 11 months ago DBV Technologies announces its participation in two investor conferences in May DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
PRESS RELEASE published on 05/09/2024 at 22:30, 1 year 11 months ago DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
BRIEF published on 05/07/2024 at 22:35, 1 year 11 months ago DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE published on 05/07/2024 at 22:30, 1 year 11 months ago DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer
Published on 04/17/2026 at 02:13, 1 hour 4 minutes ago CHAR Tech annonce l’acquisition projetée d’actifs de biocarbone au Québec, incluant un accord d’achat de 62 500 tonnes, une installation et de la propriété intellectuelle
Published on 04/17/2026 at 02:00, 1 hour 17 minutes ago UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 3 hours 45 minutes ago Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 5 hours 47 minutes ago Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 23:40, 3 hours 37 minutes ago Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 5 hours 40 minutes ago Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 6 hours 17 minutes ago Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 6 hours 42 minutes ago EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 8 hours ago EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:02, 9 hours 15 minutes ago Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 17:54, 9 hours 23 minutes ago Aéroports de Paris S.A - March 2026 traffic figures
